9 Results for "

chronic graft versus host disease

" in MedChemExpress (MCE) Product Catalog:
Products (9)

9 Results for "chronic graft versus host disease" in MCE Product Catalog:

3
3 Cited Publications
Cat. No.: HY-150298
CAS No.: 2226636-04-8
Purity:  99.71%
Synonyms: CPI-818
Target:  

Itk

Research Areas:  

Inflammation/Immunology Cancer

Soquelitinib (CPI-818) is an orally active and highly selective covalent interleukin-2-inducible kinase (ITK) inhibitor. Soquelitinib is active in six different models of T cell-mediated inflammatory and immune disease, including acute and chronic asthma, pulmonary fibrosis, systemic sclerosis (scleroderma), psoriasis, and acute graft versus host disease with Th2 cytokine product inhibition. Soquelitinib increases tumor infiltration of normal CD8 + cells that possess enhanced T effector function .
loading...
    loading...
Cat. No.: HY-P99452
CAS No.: 2155851-88-8
Synonyms: SNDX-6352

Target:  

c-Fms

Research Areas:  

Inflammation/Immunology Cancer

Axatilimab (SNDX-6352) is a humanized IgG4 antibody with high affinity to CSF-1R. Axatilimab can be used for the research of chronic graft versus host disease (cGVHD) and neoplastic diseases .
loading...
    loading...
Cat. No.: HY-13448
CAS No.: 69049-73-6
Purity:  98.19%
Synonyms: FPL 59002
Target:  

Interleukin Related

Research Areas:  

Inflammation/Immunology

Nedocromil (FPL 59002) is a mast cell stabilizer and an inhibitor of IL-8 production. Nedocromil inhibits mast cell degranulation and collagen synthesis induced by activated mast cells, indirectly interfering with IL-1β signaling. Nedocromil reduces conjunctival eosinophil infiltration and improves the cutaneous manifestations of chronic graft-versus-host disease (including reducing fibrosis, loss of fat and hair follicles, and inflammatory infiltration). Nedocromil can be used in research on chronic graft-versus-host disease, asthma, and allergic conjunctivitis .
loading...
    loading...
Cat. No.: HY-169853
CAS No.: 1189495-81-5
M351-0056 is an orally active VISTA agonist with a Kd value of 12.60 μM. M351-0056 inhibits the activation of the JAK2-STAT2 pathway, reduces the phosphorylation levels of JAK2 and STAT2, and regulates type I interferon (IFN-I) and non-canonical NF-κB pathways. M351-0056 decreases the levels of cytokines (IFN-γ, IL-17A, TNF-α, IL-2 and IL-1β). M351-0056 improves imiquimod (HY-B0180)-induced psoriasis-like skin inflammation, reduces autoantibody levels, kidney damage and immune cell expansion in mice susceptible to chronic graft-versus-host disease and lupus, and delays the progression of systemic lupus erythematosus. M351-0056 can be used in research related to psoriasis-like dermatitis and systemic lupus erythematosus .
loading...
    loading...
Cat. No.: HY-13448R
CAS No.: 69049-73-6
Synonyms: FPL 59002 (Standard)
Nedocromil (FPL 59002) (Standard) is the analytical standard of Nedocromil (HY-13448). This product is intended for research and analytical applications. Nedocromil (FPL 59002) calcium is a mast cell stabilizer and an inhibitor of IL-8 production. Nedocromil calcium inhibits mast cell degranulation and collagen synthesis induced by activated mast cells, indirectly interfering with IL-1β signaling. Nedocromil calcium reduces conjunctival eosinophil infiltration and improves the cutaneous manifestations of chronic graft-versus-host disease (including reducing fibrosis, loss of fat and hair follicles, and inflammatory infiltration). Nedocromil calcium can be used in research on chronic graft-versus-host disease, asthma, and allergic conjunctivitis .
loading...
    loading...
Cat. No.: HY-13448A
CAS No.: 101626-68-0
Synonyms: FPL 59002 calcium
Target:  

Interleukin Related

Research Areas:  

Inflammation/Immunology

Nedocromil (FPL 59002) calcium is a mast cell stabilizer and an inhibitor of IL-8 production. Nedocromil calcium inhibits mast cell degranulation and collagen synthesis induced by activated mast cells, indirectly interfering with IL-1β signaling. Nedocromil calcium reduces conjunctival eosinophil infiltration and improves the cutaneous manifestations of chronic graft-versus-host disease (including reducing fibrosis, loss of fat and hair follicles, and inflammatory infiltration). Nedocromil calcium can be used in research on chronic graft-versus-host disease, asthma, and allergic conjunctivitis .
loading...
    loading...
Cat. No.: HY-183074
Target:  

CDK Interleukin Related

Research Areas:  

Inflammation/Immunology

RO8323 is an orally active, selective CDK8/CDK19 inhibitor, with an IC50 of 2 nM against CDK8 and 3 nM against CDK19. RO8323 promotes regulatory T cell differentiation, inhibits effector T cell generation, reverses the Teff/Treg ratio, upregulates IL-10 production in myeloid cells, and suppresses the production of TNF-α, IL-6 and IL-12. RO8323 enhances immune reconstitution and prolongs cardiac allograft survival in a dose-dependent manner. RO8323 can be used in the research of chronic graft-versus-host disease, cardiac allograft rejection, acute graft-versus-host disease and experimental autoimmune encephalomyelitis .
loading...
    loading...
Cat. No.: HY-186074
CAS No.: 628321-25-5
ERβ agonist-2 (Page 72) is a selective ERβ agonist with an EC50 of 800 nM or lower. ERβ agonist-2 selectively inhibits T cell activation and/or proliferation, thereby reducing circulating T cell levels in subjects, without exerting significant effects on circulating neutrophil, monocyte or B cell levels. ERβ agonist-2 is applicable to studies of chronic heart failure after myocardial infarction, as well as graft-versus-host disease, multiple sclerosis and experimental autoimmune encephalomyelitis .
loading...
    loading...
Cat. No.: HY-150298R
CAS No.: 2226636-04-8
Synonyms: CPI-818 (Standard)
Soquelitinib (Standard) is the analytical standard of Soquelitinib (HY-150298). This product is intended for research and analytical applications. Soquelitinib (CPI-818) is an orally active and highly selective covalent interleuKin-2-inducible Kinase (ITK) inhibitor. Soquelitinib is active in six different models of T cell-mediated inflammatory and immune disease, including acute and chronic asthma, pulmonary fibrosis, systemic sclerosis (scleroderma), psoriasis, and acute graft versus host disease with Th2 cytoKine product inhibition. Soquelitinib increases tumor infiltration of normal CD8 + cells that possess enhanced T effector function .
loading...
    loading...